The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options
The incidence of melanoma has been increasing at a rapid rate, with 4%–11% of all melanoma recurrences presenting as in-transit disease. Treatments for in-transit melanoma of the extremity are varied and include surgical excision, lesional injection, regional techniques and systemic therapies. Excis...
Main Authors: | Emmanuel Gabriel, Joseph Skitzki |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2015-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6694/7/3/0830 |
Similar Items
-
Management of acral lentiginous melanoma: current updates and future directions
by: Michelle M. Dugan, et al.
Published: (2024-02-01) -
The Role of Adjuvant Radiotherapy for the Treatment of Resected High-Risk Stage III Cutaneous Melanoma in the Era of Modern Systemic Therapies
by: Seth Kibel, et al.
Published: (2023-12-01) -
The Current State of Neoadjuvant Therapy in Resectable Advanced Stage Melanoma
by: Omar Bushara, et al.
Published: (2023-06-01) -
CURRENT CONCEPTS IN THERAPY OF UVEAL MELANOMA
by: Detanac Dženana A, et al.
Published: (2015-07-01) -
Advancements in clinical developments in neo/adjuvant drug therapy for resectable melanoma: ASCO Annual Congress – June 2022
by: Dmitry A. Andreev, et al.
Published: (2023-05-01)